Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101 168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study

Clinical Chemistry

Volumn 51, Issue 6, 2005, Pages 1048-1052

  Adams, Paul C ^a   Reboussin, David M ^b   Leiendecker Foster, Cathie ^c   Moses, Godfrey C ^d   McLaren, Gordon D ^e,f   McLaren, Christine E ^e   Dawkins, Fitzroy W ^g   Kasvosve, Ishmael ^h   Acton, Ron T ^h   Barton, James C ⁱ   Zaccaro, Dan ^b   Harris, Emily L ^j   Press, Richard ^k   Chang, Henry ^l   Eckfeldt, John H ^c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d MDS Laboratories   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^g HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ SOUTHERN IRON DISORDERS CENTER   (United States)

^j CENTER FOR HEALTH RESEARCH   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IRON; TRANSFERRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEMOCHROMATOSIS; HFE GENE; HOMOZYGOSITY; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON OVERLOAD; MALE; PRIMARY MEDICAL CARE; TRANSFERRIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTEIN BINDING; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANSFERRIN;

EID: 21144458591     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.048371     Document Type: Article

References (23)

1. Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Engl J Med 2004;350:2383-97.
2. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-408.
3. Burke W, Thomson E, Khoury M, McDonnell S, Press N, Adams P, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998;280:172-8.
4. Beutler E, Felitti V, Koziol J, Ho N, Gelbart T. Penetrance of the 845G to A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
5. Asberg A, Hveem K, Thorstensen K, Ellekjaer E, Kannelonning K, Fjosne U, et al. Screening for hemochromatosis - high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36:1108-15.
6. Adams PC. Non-expressing C282Y homozygotes for hemochromatosis: minority or majority of cases? Mol Genet Metab 2000;71:81-6.
7. Andersen R, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard B. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103:2914-9.
8. Yamashita C, Adams PC. Natural history of the C282Y homozygote of the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol 2003;1:388-91.
9. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
10. Shaheen N, Lawrence L, Bacon B, Barton J, Barton N, Galanko T, et al. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end-organ damage. Am J Gastroenterol 2003;98:1175-80.
11. Barash C. Genetic discrimination and screening for hemochromatosis: then and now. Genet Test 2000;4:213-8.
12. Adams PC, Kertesz AE, McLaren C, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron binding capacity, transferrin saturation and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000;31:1160-4.
13. Hickman P, Hourigan L, Powell LW, Cordingley F, Dimenski G, Ormiston BSJFW, et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous hemochromatosis. Gut 2000;46:405-9.
14. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
15. Adams PC, Bhayana V. Unsaturated iron binding capacity, a screening test for hemochromatosis? Clin Chem 2000;46:1870-1.
16. McLaren C, Barton J, Adams P, Harris E, Acton R, Press N, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003;325: 53-62.
17. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening of a racially diverse population. N Engl J Med 2005;352:1769-78.
18. DeLong E, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988;44:837-44.
19. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993;30:521-39.
20. Obuchowski N, Lieber M, Wians F. ROC curves in clinical chemistry: Uses, misuses, and possible solutions. Clin Chem 2004;50:1118-25.
21. Zweig M, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
22. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004;39:21-9.
23. Guillygomarch A, Jacquelinet C, Moirand R, Vincent Q, David V, Deugnier Y. Circadian variations of transferrin saturation levels in iron-overloaded patients: implications for screening of C282Y-linked haemochromatosis. Br J Haematol 2003;120:359-63.